We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Amyloid Fibril Components Exhibit Distinct Molecular Recycling Properties

By LabMedica International staff writers
Posted on 15 Jun 2011
A publication revealed that the protein fragments comprising amyloid fibrils - abnormal strands of protein associated with some two dozen diseases ranging from Alzheimer's to type-2 diabetes – undergo a continuous cycle of dissociation and reassociation.

Previously NMR-guided simulations had shown that the two fragments, amyloid-beta-40 and amyloid-beta-42, seemed to feature highly different conformational states, with the C-terminus of amyloid-beta-42 being more structured than that of the amyloid-beta-40 fragment. More...
Now, in a paper published in the April 12, 2011, online edition of the Journal of the American Chemical Society investigators at the Institute for Research in Biomedicine (Barcelona, Spain) analyzed the movement of protein fragments within amyloid fibrils.

The investigators used an advanced technique called electrospray ionization mass spectrometry to monitor hydrogen/deuterium exchange in amyloid-beta-fibrils. They found after monitoring recycling for 40 days that both amyloid-beta-40 and amyloid-beta-42 molecules recycled within the fibril population, although to different extents. After 40 days, 80% of the molecules making up amyloid-beta-40 fibrils underwent recycling while only 30% did so in amyloid-beta-42 fibrils. These observations imply that amyloid-beta-42 recycled more slowly, which has implications for understanding the role of amyloid-beta-fibrils in neurotoxicity and for designing therapeutic strategies against Alzheimer's disease.

"In the context of Alzheimer's disease, demonstrating that recycling occurs in the fibrils is a step forward but it is also crucial to identify the recycling species involved; whether they are individual amyloid-beta units or small aggregates made of several units," said senior author Dr. Natalia Carulla, professor of chemistry at the Institute for Research in Biomedicine. "It will be important to address if differences in the recycling species within amyloid-beta-40 and amyloid-beta-42 fibrils are relevant in the development of Alzheimer's disease. We are now working towards this aim. Once we have this information, we will be in a position to devise new therapeutic strategies that can modulate recycling."

Related Links:
Institute for Research in Biomedicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.